Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005351 · ClinicalTrials.gov registry record · Phase 2
"SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia
A Phase 2 study, sponsored by Swing Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT05005351: Completed Phase 2 study, sponsored by Swing Therapeutics.
NCT05005351 is a Phase 2 study that has completed, run by Swing Therapeutics. The registered enrollment target is 67 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05005351, a Phase 2 study, has completed, sponsored by Swing Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a non-significant risk, multi-center, randomized, active-controlled study to compare the effectiveness of two digital therapies in the management of fibromyalgia over 12 weeks. The primary endpoint is mean change from baseline to Week 12 in the weekly revised Fibromyalgia Impact Questionnaire (FIQ-R) total score.
Primary Outcome
FIQ-R total score ranges between 0-100 with a reduction in score indicating reduced fibromyalgia severity.
Interventions
- DEVICE Digital ACT
- DEVICE Digital Symptom Tracker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2021-07-09 |
| Phase | Phase 2 |
What the finished NCT05005351 record still lists
NCT05005351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Digital ACT is the first listed.
NCT05005351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05005351 about?
NCT05005351 is a clinical study titled ""SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia". This is a non-significant risk, multi-center, randomized, active-controlled study to compare the effectiveness of two digital therapies in the management of fibromyalgia over 12 weeks. The primary endpoint is mean change from baseline to Week 12 in the weekly revised Fibromyalgia Impact Questionnair...
What is the current status of trial NCT05005351?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2020-10-28. Estimated completion is 2021-07-09.
What interventions are being tested in trial NCT05005351?
The interventions under investigation include: Digital ACT (DEVICE), Digital Symptom Tracker (DEVICE).
Who is sponsoring clinical trial NCT05005351?
This trial is sponsored by Swing Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05005351's enrollment target sits among peer trials
67 974th of 2000 higher than 1,026 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI